Patient perspectives on SLE, refractory APS, and biologic drug use during pregnancy

Jara van Woerkom, Merlijn Wind, Yoe Kie Onno Teng, Titia Lely, Jamy Pullen, Gerard Jansen, Luis Perez-Garcia, Radboud Dolhain, Maarten Limper, Judith Kooiman, Department of Obstetrics, University Medical Center Utrecht, The Netherland, Department of Obstetrics, Leiden University Medical Center, The Netherlands, Department of Nephrology, Leiden University Medical Center, The Netherlands, Dutch National Patient Association for Lupus Erythematosus , The Netherlands, Department of Hematology, Erasmus University Medical Center, The Netherlands, Department of Rheumatology, Erasmus University Medical Center, The Netherlands, Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, The Netherlands, Department of Obstetrics, Erasmus University Medical Center, The Netherlands

Lupus: An International Journal

Published online on March 26, 2026

Abstract

Lupus, Volume 35, Issue 7, Page 699-708, June 2026.
PurposeWomen with Systemic Lupus Erythematosus (SLE) and/or Antiphospholipid Syndrome (APS) have an increased risk of pregnancy complications. This study explored their perspectives on pregnancy, pregnancy complications, and medication use during ...